The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis-Reference-Cited by-同舟云学术

The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis

Published:2016-06-22 Issue:6 Volume:20 Page:509-516
ISSN:1203-4754
Container-title:Journal of Cutaneous Medicine and Surgery
language:en
Short-container-title:J Cutan Med Surg

Author:

AbuHilal Mohn’d¹,Walsh Scott¹,Shear Neil¹

Affiliation:

1. Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Center and University of Toronto, Toronto, ON, Canada

Abstract

Background: Major advances have been made in the understanding of the pathophysiology of psoriasis. Objectives: The authors review the role of interleukin (IL) 17 in the pathogenesis of psoriasis and provide updates on approved and investigational therapies targeting IL-17 and the IL-17 receptor. Methods: A PubMed search was performed for relevant literature. Conclusion: The IL-23/Th17 signaling pathway (including IL-17) plays a central role in the pathogenesis of psoriasis. Biologic agents that block IL-17 (secukinumab and ixekizumab) or its receptor (brodalumab) are effective and safe for the treatment of psoriasis.

Publisher

SAGE Publications

Subject

Dermatology,Surgery

Link

http://journals.sagepub.com/doi/pdf/10.1177/1203475416651605

Reference60 articles.

1. Psoriasis

2. New insights of T cells in the pathogenesis of psoriasis

3. Etiology and Pathogenesis of Psoriasis

4. Interleukin 17A: Toward a new understanding of psoriasis pathogenesis

5. Development, cytokine profile and function of human interleukin 17–producing helper T cells

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of serial QuantiFERON‐TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti‐IL‐17 treatment (secukinumab and ixekizumab): Real‐world data from a tuberculosis‐endemic country;Australasian Journal of Dermatology;2024-07

2. Ex vivo cell-based assay for assessment of response to TNF inhibitors in patients with rheumatic diseases;Rheumatology;2024-05-25

3. A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians;Dermatology and Therapy;2022-11-01

4. Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real‐world experience;Dermatologic Therapy;2022-10-31

5. Roles of IL-25 in Type 2 Inflammation and Autoimmune Pathogenesis;Frontiers in Immunology;2021-05-28